Article Text
Abstract
Systemic amyloidosis can be hereditary or acquired. The autosomal dominant hereditary transthyretin amyloidosis and the acquired light-chain amyloidosis, the result of a plasma cell dyscrasia, are multisystem disorders with cardiovascular, autonomic and peripheral nerve involvement. There are numerous investigational modalities available to diagnose systemic amyloidosis and to assess the extent of organ involvement, but it is frequently misdiagnosed due to its heterogeneous clinical presentations and misleading investigation findings. An accurate and timely diagnosis of amyloid neuropathy can greatly impact on the outcomes for patients, especially as there will soon be new gene-silencing treatments for hereditary transthyretin amyloidosis.
- amyloid
- neuropathy
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Cardiac transthyretin amyloidosis
- The transthyretin amyloidoses: advances in therapy
- Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response
- Amyloid in the cardiovascular system: a review
- A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK
- Amyloidosis
- Amyloid diseases of the heart: assessment, diagnosis, and referral
- Diagnosis and management of sensory polyneuropathy
- Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy
- A rare cause of weakness